On May 25, 2021 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that the Board of Directors has declared a quarterly dividend of $0.65 per share of the company’s common stock for the third quarter of 2021 (Press release, Merck & Co, MAY 25, 2021, View Source [SID1234580550]). Payment will be made on July 7, 2021 to shareholders of record at the close of business on June 15, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 25, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported a publication in Nature Cancer that gives new insight into the mechanism of long-term durability of effect in acute lymphoblastic leukemia (ALL) patients treated with AUTO1 (Press release, Autolus, MAY 25, 2021, View Source [SID1234580566]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AUTO1 CAR T cells from pediatric ALL patients who still had CAR T cells detectable in the blood more than two years after their treatment were compared with patients who had lost their AUTO1 CAR T cells one to two months post treatment. The study shows that a subset of AUTO1 CAR T cells called Stem Cell Memory T-cells (TSCM) appear critical in both the initial anti-leukemic response and for long term immune surveillance. This suggests that this sub-group of AUTO1 CAR T cells contribute to the long-term durability of effect that AUTO1 has in these patients.

"AUTO1 has been designed to have an optimized interaction between its chimeric antigen receptor and the CD19 target on cancer cells," said Dr Martin Pule, Founder and Chief Scientific Officer of Autolus. "This means AUTO1 can efficiently deliver a kill and disengage rapidly like a normal T cell, leading to less exhaustion and less T cell differentiation. This unique property of AUTO1 potentially contributes to the enrichment and maintenance of this stem cell memory subset that appears to be critical to the long-term durability observed in pediatric ALL patients treated with AUTO1."

On May 25, 2021 ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported that Dr. David R. Parkinson, Chief Executive Officer of ESSA, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference (Press release, ESSA, MAY 25, 2021, View Source [SID1234580582]). Dr. Parkinson, along with Peter Virsik, ESSA’s Chief Operating Officer, and David S. Wood, ESSA’s Chief Financial Officer, will be available for one-on-one meetings. The conference will take place from June 1 – June 4, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the fireside chat can be accessed on the Investors/Events & Presentations section of ESSA’s website at www.essapharma.com. Following the event, the webcast will be archived on the Company’s website for 90 days.

On May 25, 2021 EDH Nuclear Medicine and Healthcare Services Ltd. Co. and SHINE Medical Technologies LLC reported that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries (Press release, Shine Medical Technologies, MAY 25, 2021, View Source;pk_kwd=shine-edh-enter-distribution-agreement-for-shines-non-carrier-added-lu-177 [SID1234580664]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, EDH will sell and distribute SHINE’s non-carrier-added, cGMP lutetium-177 (Lu-177) manufactured in Janesville, Wis.

Lu-177 is a low-energy beta-particle emitter that works by directly irradiating cancer cells after being delivered to the cancer site by a targeting molecule. Lu-177 is used to treat neuroendocrine cancers and also shows promise for the treatment of metastatic prostate and other cancers. SHINE’s Lu-177 production process enables the company to produce the high specific activity, non-carrier-added Lu-177 required by today’s customers.

"At EDH, we are keen to provide state-of-the-art theranostic products and solutions to our stakeholders and SHINE’s n.c.a Lu-177 will enable us to offer high specific activity Lu-177 to patients while addressing hospitals’ risks associated with waste management," said Hasan Ulas Ozcan, general manager of EDH Nuclear Medicine and Healthcare Services. "We are happy to partner with an innovative company like SHINE, which is aiming to become the world’s leading producer of medical isotopes, and we hope to extend our regions of operation with SHINE after successfully launching SHINE’s n.c.a. Lu-177 in selected countries."

"SHINE’s Lu-177 has the potential to improve the patient outcomes around the world with certain cancers," said Katrina Pitas, vice president and general manager of SHINE Therapeutics. "EDH is a strong partner for SHINE. Hasan and his team know the Eurasia region well and we look forward to working with them to ensure patients have access to this promising therapeutic isotope."

On May 25, 2021 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, reported that Daphne Zohar, Founder and CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2nd at 9:00 AM EST (Press release, PureTech Health, MAY 25, 2021, View Source [SID1234584764]). A webcast of the presentation will be available at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!